DOI: 10.1055/s-00023610

Drug Research

LinksSchließen

Referenz

Yen K, Travins J, Wang F. et al.
AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations.

Cancer Discovery
7: 478-493

Bibliographische Angaben herunterladen

Suchen in: